Adjuvant Cemiplimab or Placebo in High-Risk Cutaneous Squamous-Cell Carcinoma

Skin Cancer

Baseline D-dimers as predictive marker of efficacy of cemiplimab treatment in cutaneous squamous cell carcinoma

Eur J Cancer

Geidel G, Adam L, Bänsch S, Fekade N, Degenhardt S, Rünger A, Kött J, Zell T, Heidrich I, Smit DJ, Greinert R, Volkmer B, Pantel K, Mohr P, Hauschild A, Schneider SW, Gebhardt C

doi: 10.1016/j.ejca.2025.115639

Genitourinary Cancer

Adjuvant Nivolumab in High-Risk Muscle-Invasive Urothelial Carcinoma: Expanded Efficacy From CheckMate 274

J Clin Oncol

Galsky MD, Witjes JA, Gschwend JE, Milowsky MI, Schenker M, Valderrama BP, Tomita Y, Bamias A, Lebret T, Shariat SF, Park SH, Agerbaek M, Jha G, Stenner F, Ye D, Giudici F, Dutta S, Askelson M, Nasroulah F, Zhang J, Brophy L, Bajorin DF

doi: 10.1200/JCO.24.00340

Head and Neck Cancer

Induction vs Adjuvant Chemoradiotherapy in Patients With High-Risk N2 to N3 Nasopharyngeal Carcinoma: A Phase 3 Randomized Clinical Trial

JAMA Oncol

Guo SS, Li XY, Liu LT, Jia GD, Liu SL, Sun XS, Luo DH, Yang JH, Xie SY, Li YF, Lv X, Xiang YQ, Xia WX, Sun R, Liu Q, Li JB, Wang P, Yang Q, Wang L, Wen DX, Jin J, Lin JY, Mo HY, Guo L, Zhao C, Guo X, Chen QY, Tang LQ, Mai HQ

doi: 10.1001/jamaoncol.2025.1597

Gynecologic Cancer

Pembrolizumab or Placebo Plus Adjuvant Chemotherapy With or Without Radiotherapy For Newly Diagnosed, High-Risk Endometrial Cancer: Results in Mismatch Repair-Deficient Tumors

J Clin Oncol

Slomovitz BM, Cibula D, Lv W, Ortaç F, Hietanen S, Backes F, Kikuchi A, Lorusso D, Dańska-Bidzińska A, Samouëlian V, Barretina-Ginesta MP, Vulsteke C, Lai CH, Pothuri B, Zhang Y, Magallanes-Maciel M, Amit A, Guarneri V, Zagouri F, Bell M, Welz J, Eminowicz G, Hruda M, J Willmott L, Lichfield J, Wang W, Orlowski R, Aktan G, Gladieff L, Van Gorp T

doi: 10.1200/JCO-24-01887

CHICAGO 2025

Head and Neck Cancer

LBA2: NIVOPOSTOP: Adding nivolumab to adjuvant cisplatin-radiotherapy improves DFS in high-risk patients with LA-SCCHN

Head and Neck Cancer

Antihypertensive drugs and survival outcomes in oropharyngeal squamous cell carcinoma patients

J Natl Cancer Inst

Lee CM, Wadsworth BJ, Urban R, Clark MA, Shi R, Sit D, Hamilton SN, Bennewith KL

doi: 10.1093/jnci/djaf056

Multiple Myeloma (MM)

Real-world characteristics and outcomes of patients with high-risk and non-high-risk smoldering multiple myeloma using the Flatiron Health database

Blood Cancer J

Rajkumar SV, Mateos MV, Schaeffer M, Lin X, Bathija S, Gupta-Werner N, Lam A, Carson R, Dennis R, Kaila S, Matt K, Duran J, Lonial S

doi: 10.1038/s41408-024-01170-z

Skin Cancer

Human papillomavirus-related squamous cell carcinomas after blood or marrow transplantation-a BMTSS report

J Natl Cancer Inst

Holmqvist AS, Meng Q, Landier W, Hageman L, Francisco LF, Ross ES, Balas N, Bosworth A, Te HS, Bhatia R, Wong FL, Weisdorf D, Armenian SH, Bhatia S

doi: 10.1093/jnci/djaf021

Gastrointestinal Cancer

First-Line Tislelizumab Plus Chemotherapy for Esophageal Squamous Cell Carcinoma with Programmed Death-Ligand 1 Expression ≥ 1%: A Retrospective Analysis of RATIONALE-306

Adv Ther

Xu J, Kato K, Hubner R, Park SR, Kojima T, Ishihara R, Wyrwicz L, Van Cutsem E, Jimenez-Fonseca P, Wu H, Wang L, Yan S, Shi J, Kadva A, Yoon HH

doi: 10.1007/s12325-025-03115-9

Related content

Baseline D-dimers as predictive marker of efficacy of cemiplimab treatment in cutaneous squamous cell carcinoma

Adjuvant Nivolumab in High-Risk Muscle-Invasive Urothelial Carcinoma: Expanded Efficacy From CheckMate 274

Induction vs Adjuvant Chemoradiotherapy in Patients With High-Risk N2 to N3 Nasopharyngeal Carcinoma: A Phase 3 Randomized Clinical Trial

Pembrolizumab or Placebo Plus Adjuvant Chemotherapy With or Without Radiotherapy For Newly Diagnosed, High-Risk Endometrial Cancer: Results in Mismatch Repair-Deficient Tumors

LBA2: NIVOPOSTOP: Adding nivolumab to adjuvant cisplatin-radiotherapy improves DFS in high-risk patients with LA-SCCHN

Antihypertensive drugs and survival outcomes in oropharyngeal squamous cell carcinoma patients

Real-world characteristics and outcomes of patients with high-risk and non-high-risk smoldering multiple myeloma using the Flatiron Health database

Human papillomavirus-related squamous cell carcinomas after blood or marrow transplantation-a BMTSS report

First-Line Tislelizumab Plus Chemotherapy for Esophageal Squamous Cell Carcinoma with Programmed Death-Ligand 1 Expression ≥ 1%: A Retrospective Analysis of RATIONALE-306